Liet al.,Science 376 , eabi9591 (2022) 15 April 2022 5 of 13
Healthy Mild Moderate SevereCD3KIRDABCHC Mild
ModerateSevere05101520KIR+/CD8+ T cells (%)*************without
vasculitiswith
vasculitis02468CD25hiCD127lo/CD4+^ T cells (%)CD4+ Tregwithout
vasculitiswith
vasculitis020406080100KIR+/NK cells (%)KIR+ NKHC Influenza-
infected0510152025KI+R
/CD+ 8
T cells (%)KIR+ CD8
***HC Influenza-
infected012345CD2hi 5
CD12lo 7
/CD4+ T cells (%)CD4+ TregHC
ModerateSevere051015KIR+/CD8+ T cells (%)*
*HC
COVID-19051015KIR+/CD+ 8
T cells (%)**HC
COVID-1905101520KIR+/CD8+
T cells (%)****without
vasculitiswith
vasculitis05101520KI+R
/CD8+^ Tcells (%)**KIR+ CD8Fig. 3. Increased KIR+CD8+T cells in infectious diseases.(A) Representa-
tive contour plots and summary scatter plots showing the percentage of
KIR+cells in CD8+T cells from the blood of 17 HCs and 53 COVID-19 patients
with varying disease severity (mild,N= 23; moderate,N= 17; severe,
N= 13). **P< 0.0001; Mann-Whitney test (left). P< 0.01; *P< 0.001;
**P< 0.0001; Kruskal-Wallis test followed by multiple comparisons test
(right). (B) Frequency of KIR+CD8+T cells, CD4+Tregs(CD25hiCD127lo), and
KIR+NK cells in the blood of COVID-19 patients with or without vasculitis.
**P< 0.01; Mann-Whitney test. (C) Frequency of CD8+T cells expressing
KIRtranscripts (KIR3DL1,KIR3DL2,KIR2DL3, orKIR2DL1) in the bronchoal-
veolar lavage fluid of HCs (N= 4) versus COVID-19 patients (N=9)(left;
**P< 0.01; Mann-Whitney test) and HCs versus COVID-19 patients with
moderate (N= 3) or severe (N= 6) disease (right; *P< 0.05; Kruskal-Wallis
test followed by multiple comparisons test). (D) Frequency of KIR+CD8+
T cells and CD4+Tregs(CD25hiCD127low) in the blood of HCs (N= 17) versus
influenza-infected patients (N= 7). ***P< 0.001; Mann-Whitney test.RESEARCH | RESEARCH ARTICLE